Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsConsultation-liaison — hepatic encephalopathy and advanced transplant psychiatry

Psych MEQs / SAQs · Consultation-liaison — hepatic encephalopathy and advanced transplant psychiatry

Recurrent HE and liver transplant listing psychosocial evaluation (MEQ)

FRANZCP-style MEQ integrating HE classification/management with advanced liver transplant psychosocial evaluation, alcohol-associated disease, depression, and adherence.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the C-L psychiatry registrar. A 52-year-old man with decompensated alcohol-associated cirrhosis has had three admissions for overt hepatic encephalopathy in six months. Asterixis is present on day 1; he improves with lactulose. Hepatology is considering transplant evaluation. He reports 8 months self-reported abstinence, attends mutual-help groups irregularly, has moderate depression with passive death wishes, and two clinic DNAs. Surgeons ask if he is a 'psychiatric contraindication.' (i) Define and classify HE relevant to this stem (West Haven / covert–overt / type). (ii) List key precipitants and acute management principles including one evidence-based secondary prevention agent. (iii) Outline structured pre-transplant psychosocial domains (SIPAT/ISHLT-style). (iv) Discuss absolute vs relative psychosocial barriers and a management plan before MDT. (v) Name two evidence anchors (named trials/meta-analyses/guidelines). (20 marks)

Model answer

Reveal model answer

(i) Definition and classification. HE is brain dysfunction from liver insufficiency and/or portosystemic shunting after alternative causes are considered.[1] This man has type C (cirrhosis) disease with recurrent episodic overt HE (West Haven at least grade II with asterixis; not covert-only). Covert HE (minimal HE ± mild grade I) is a related construct for subtler cases.[1][2]

(ii) Precipitants and acute/secondary prevention. Hunt infection, GI bleed, constipation, electrolytes/dehydration, sedatives (especially benzodiazepines), and other triggers.[2] Acute care: safety/ABC, treat precipitants, lactulose as cornerstone, avoid benzo-first sedation. For recurrent breakthrough after remission, rifaximin (Bass RCT: 550 mg twice daily oral reduced recurrence, often with lactulose background) is the high-yield evidence anchor.[2][3]

(iii) Psychosocial domains. Structure assessment across readiness/health literacy; social support; psychopathology (depression, suicide risk); substance recovery engagement and monitoring plan; adherence history (DNAs, regimen examples); and decision-specific capacity for lifelong immunosuppression. SIPAT operationalises many of these domains; ISHLT-style recommendations emphasise multidisciplinary documented process.[4]

(iv) Barriers and plan. Avoid global “psychiatric contraindication.” High-barrier until resolved: uncontrolled major illness impairing cooperation, active untreated substance use without engagement, absent support for complex regimen. Relative/modifiable: treated depression, sustained abstinence with structure, improvable attendance. Plan: treat depression and suicide risk; intensify alcohol recovery structure and collateral; education/teach-back; reduce DNA barriers; HE secondary prevention adherence; reassess capacity when lucid; present residual risk transparently to MDT rather than binary clear/not clear.[4][5][6]

(v) Evidence anchors. Examples: Ferenci working-party nomenclature; AASLD/EASL 2014 HE guideline; Bass rifaximin RCT; SIPAT (Maldonado); Dew depression/anxiety outcome meta-analysis; Dew substance relapse meta-analysis; Mathurin early LT for severe AH as related alcohol-policy viva counterpoint to rigid universal abstinence myths.[1][2][3][4][5][6]

References

  1. [1]Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998 Hepatology, 2002.PMID 11870389
  2. [2]Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Hepatology, 2014.PMID 25042402
  3. [3]Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med, 2010.PMID 20335583
  4. [4]Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates Psychosomatics, 2012.PMID 22424160
  5. [5]Dew MA, Rosenberger EM, Myaskovsky L, et al. Depression and Anxiety as Risk Factors for Morbidity and Mortality After Organ Transplantation: A Systematic Review and Meta-Analysis Transplantation, 2015.PMID 26492128
  6. [6]Dew MA, DiMartini AF, Steel J, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs Liver Transpl, 2008.PMID 18236389